ReNeuron Group PLC

ReNeuron to present at regenerative medicine conference


ReNeuron Group (LON:RENE) will present at a key regenerative medicine conference in front of representatives from the funding community, large pharmaceuticals companies and the NHS. 

‘Exploiting Market Opportunities in Regenerative Medicine’ conference has been organised by the government sponsored ‘Technology Strategy Board’ (TSB), to showcase grant recipients.

ReNeuron’s chief scientific officer Dr John Sinden and Head of Cell Development Dr Kenny Pollock will describe how the two grants received from the TSB helped the company to successfully begin the ‘ground-breaking’ UK Phase I clinical trial for ReN001 - a stem cell therapy for disabled stroke patients.

The grants also helped ReNeuron progress late pre-clinical activities for ReN009 - a therapy for peripheral arterial disease.

The conference will take place today, September 21, at the King's Fund, Cavendish Square, London. 

The presentations at the event will focus on how the TSB funding has assisted the company in addressing key challenges in the regenerative medicine field, as well as the resulting commercial opportunities.

In February 2010, ReNeuron received the green light to begin the first stage of clinical trials for ReN001. Later in June, it secured site approval in Scotland, which paved the way to start patient recruitment.

In the most recent update two weeks ago, the company told investors that it was encouraged by the progress being made. Assuming a successful pre-treatment evaluation period once enrolled, we maintain our expectation of initial patient dosing towards the end of the year,” the group said.

ReNeuron believes that ReN001 could radically alter the treatment of disabled stroke patients.

It is hoped the stem cells, which are injected directly into the damaged area of the brain during a minor operation similar to a biopsy, will enable patients to have a more “independent life”.

ReNeuron’s ReN009 uses the same cells injected into stroke patients. It is being developed to reverse the effects of peripheral arterial disease in the leg, brought on by conditions such as diabetes.

Quick facts: ReNeuron Group PLC

Price: £2.05

Market: LSE
Market Cap: £65.26 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...



ReNeuron signs retinal stem cell exclusivity agreement

ReNeuron Group Plc (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking its hRPC retinal stem cell technology and therapeutic programmes. CFO Michael Hunt says they're hoping the exclusivity agreement with an unnamed US-based speciality...

on 11/7/18

2 min read